Immunohistochemistry (IHC) and in situ hybridization (ISH)
Experts predict over 680,000 deaths annually due to breast cancer, making it a leading cause of death in women.1 In developed countries breast cancer-related mortality has declined, in part due to therapeutic advances and evolution of biomarkers.2,3 For example, Immunohistochemistry (IHC) analysis and in situ hybridization (ISH) analysis provide important information related to tumor biology, help profile types of breast cancer and may improve treatment decisions.4
Clinical benefit
With proven accuracy, VENTANA breast cancer diagnostic assays help you identify patients other assays can miss—so you can deliver the right test, with clinical confidence in the shortest time possible.